Resultados de la búsqueda 921-930 of 4308 for Relapse

  1. Oncología (médica) - Ensayos clínicos

    ... Relapsed/Refractory Multiple Myeloma (RRMM). Study of Gastric Cancer and Limited Peritoneal Metastasis Using Robotic Cytoreduction and Hyperthermic ...

  2. Ensayos clínicos - Neurología

    Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and ...

  3. Oncología (médica) - Ensayos clínicos

    Inotuzumab Ozogamicin In Treating Younger Patients With Relapsed Or Refractory CD22 Positive B Acute Lymphoblastic Leukemia. Rochester, Minn. This phase II ...

  4. Hematología - Ensayos clínicos

    AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL. Rochester, Minn. This is a Phase 2 global, multi-center, open-label study ...

  5. Neurología - Ensayos clínicos

    Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and ...

  6. Cirugía plástica - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to describe a new surgical technique for nipple reconstruction in female-to-male transgender chest wall reconstruction and ...

  7. Oncología (médica) - Ensayos clínicos

    NL-201 in Patients With Relapsed or Refractory Cancer. Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to ...

  8. Oncología (médica) - Ensayos clínicos

    A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small ...

  9. Prolapso uterino - Médicos y departamentos - Mayo Clinic

    Obtén más información sobre los síntomas y los posibles tratamientos, incluida la reparación quirúrgica, para este trastorno del suelo pélvico.

  10. Oncología (médica) - Ensayos clínicos

    This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory ...